

State of Oklahoma SoonerCare

Neulasta® (pegfilgrastim), Nivestym® (filgrastim-aafi), Nyvepria® (pegfilgrastim-apgf), Releuko® (filgrastim-ayow), Rolvedon® (eflapegrastim-xnst), Ryzneuta® (efbemalenograstim alfa-vuxw), Stimufend® (pegfilgrastim-fpgk) and Udenyca® (pegfilgrastim-cbqv) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
□Physician billing (HCPCS code:) □Pharmacy	billing (NDC:)
Dose:Dosing Regimen:	sing Regimen: Start Date (or date of next dose):	
Expected Treatment Duration/Number of Doses:		
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fa	X:
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	_ Prescriber Fax:	Specialty:
Criteria Cri		
Ryzneuta® (efbemalenograstin (pegfilgrastim-cbqv), please in A. Diagnosis: B. Please provide a patient	n alfa-vuxw), Stimufend [®] (positional properties of the diagnosis and interest of the diagnosis of the	obbk), Rolvedon [®] (eflapegrastim-xnst), pegfilgrastim-fpgk) and Udenyca [®] information: Int reason why the member cannot use tim-pbbk), Neulasta [®] Onpro [®] (pegfilgrastim),
authorization. 2. For Nivestym® (filgrastim-aafi) information: A. Diagnosis: B. Please provide a patient	and Releuko [®] (filgrastim-a	a medical only benefit without prior ayow), please indicate the diagnosis and at reason why the member cannot use Zarxio® (filgrastim-sndz):
Additional Information:		
the best of my knowledge.		Date:and all information is true and correct to f necessary. Failure to complete this form in full will

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 208 4/25/2024